These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30540684)

  • 21. Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure.
    Pinto G; Tondi L; Gemma M; De Marco A; Silipigni C; Spoladore R; Margonato A; Fragasso G
    J Cardiovasc Pharmacol; 2019 May; 73(5):301-306. PubMed ID: 30855406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
    Norberg H; Bergdahl E; Lindmark K
    Cardiovasc Ther; 2019; 2019():6745074. PubMed ID: 31772613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacubitril/Valsartan (Entresto) for Heart Failure.
    Cheng J
    Am Fam Physician; 2016 Oct; 94(8):611-612. PubMed ID: 27929235
    [No Abstract]   [Full Text] [Related]  

  • 25. Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan.
    Adie SK; Ketcham SW; Abdul-Aziz AA; Thomas MP; Konerman MC
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):403-406. PubMed ID: 34173810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS; McMurray JJ
    Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    Hu J; Wu Y; Zhou X; Wang X; Jiang W; Huo J; Shan Q
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):445-451. PubMed ID: 33030857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients.
    Karagodin I; Kalantari S; Yu DB; Kim G; Sayer G; Addetia K; Tayazime S; Weinert L; Yamat M; Uriel N; Lang R; Mor-Avi V
    Int J Cardiovasc Imaging; 2020 Feb; 36(2):271-278. PubMed ID: 31583499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Shaddy R; Canter C; Halnon N; Kochilas L; Rossano J; Bonnet D; Bush C; Zhao Z; Kantor P; Burch M; Chen F
    Am Heart J; 2017 Nov; 193():23-34. PubMed ID: 29129252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.
    Dereli S; Bayramoğlu A; Kaya A
    J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):13-20. PubMed ID: 31714330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
    Dashwood A; Vale C; Laher S; Chui F; Rheault H; Gan J; Wong YW
    Heart Lung Circ; 2020 Nov; 29(11):1688-1695. PubMed ID: 32327307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
    Pellicori P; Urbinati A; Shah P; MacNamara A; Kazmi S; Dierckx R; Zhang J; Cleland JGF; Clark AL
    Eur J Heart Fail; 2017 Jun; 19(6):768-778. PubMed ID: 28244205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
    Del Buono MG; Bonaventura A; Vecchié A; Wohlford GF; Dixon DL; Van Tassel BW; Abbate A
    J Cardiovasc Pharmacol; 2020 Feb; 75(2):105-107. PubMed ID: 31815825
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.